EUVIMEDOpdag EUVIMED
Fallbericht

First‐in‐Human Use of a Novel Perfusion‐Channel Drug‐Coated Balloon to Manage Coronary Artery Perforation During Chronic Total Occlusion Intervention: A Case Report

Lingjun Zeng, Dongsheng Li

Catheterization and Cardiovascular Interventions · 2026-08-05

DOI: 10.1002/ccd.70788 ↗

At a glance

Fallbericht in Catheterization and Cardiovascular Interventions, published online on 2026-08-05. Written by Lingjun Zeng and 1 co-authors. Institution: Department of Cardiology, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China. Major MEDLINE topics: Coronary Occlusion, Angioplasty, Balloon, Coronary, Coronary Vessels, Cardiac Catheters. 10 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Coronary artery perforation (CAP) remains a serious complication of percutaneous coronary intervention (PCI), with an increased incidence during chronic total occlusion (CTO) procedures. Conventional management using covered stents often compromises side branches and limits future revascularization options, while prolonged balloon inflation, though simpler, interrupts distal flow and increases ischemic risk. We present a case of a 54‐year‐old male with coronary heart disease, hypertension, and diabetes who underwent PCI for a severe proximal stenosis and a mid‐segment CTO of the left anterior descending artery (LAD). Following small balloon predilation, an Ellis type II perforation occurred in the LAD main vessel region. A novel perfusion‐channel drug‐coated balloon (PcDCB) was immediately deployed, covering the proximal LAD and the ostium of a large diagonal branch (D1). Inflation at 6 atm for 10 minutes successfully sealed the perforation while maintaining TIMI 2 flow into D1 via its side channels. Post‐procedural angiography and echocardiography confirmed complete sealing without pericardial effusion. This first‐in‐human experience demonstrates that the PcDCB can effectively manage CAP by achieving simultaneous mechanical sealing and distal perfusion, and in this case additionally treated a severely stenotic proximal segment, potentially avoiding stent implantation while preserving the option for future staged revascularization. The drug‐coated property may offer added rationale for treating diseased segments, though its specific role in perforation management per se warrants further investigation.

Subjects

MeSH terms (MEDLINE)

Coronary OcclusionAngioplasty, Balloon, CoronaryCoronary VesselsCardiac CathetersCoated Materials, BiocompatibleHeart InjuriesCardiovascular AgentsVascular System InjuriesHumansMaleMiddle AgedCoronary AngiographyTreatment OutcomeChronic DiseaseEquipment DesignSeverity of Illness Index

Substances

Coated Materials, BiocompatibleCardiovascular Agents

Authors and institutions

  • Department of Cardiology, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, China.

Cite

APA

Zeng, L., & Li, D. (2026). First‐in‐Human Use of a Novel Perfusion‐Channel Drug‐Coated Balloon to Manage Coronary Artery Perforation During Chronic Total Occlusion Intervention: A Case Report. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70788

Vancouver

Zeng L, Li D. First‐in‐Human Use of a Novel Perfusion‐Channel Drug‐Coated Balloon to Manage Coronary Artery Perforation During Chronic Total Occlusion Intervention: A Case Report. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.70788

BibTeX
@article{Zeng2026,
  author = {Zeng, Lingjun and Li, Dongsheng},
  title = {First‐in‐Human Use of a Novel Perfusion‐Channel Drug‐Coated Balloon to Manage Coronary Artery Perforation During Chronic Total Occlusion Intervention: A Case Report},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  doi = {10.1002/ccd.70788}
}
Start for free →